The 2026 Regulatory Survival Guide: MoCRA & FDA 21 CFR Part 11

The regulatory landscape for cosmetics and dietary supplements has reached a critical turning point. With the full enforcement of the Modernization of Cosmetics Regulation Act (MoCRA) and tightening FDA oversight, compliance is no longer a voluntary best practice — it is a mandatory requirement for staying in business.

Whether you manufacture supplements, cosmetics, or both, understanding these regulations is essential to avoiding costly enforcement actions and protecting your brand.

What Is MoCRA and Why Does It Matter?

The Modernization of Cosmetics Regulation Act, signed into law in December 2022, represents the most significant update to cosmetics regulation since 1938. For the first time, the FDA has been given real enforcement power over the cosmetics industry — and many of these requirements overlap with supplement manufacturing facilities.

Key MoCRA Requirements

Mandatory Facility Registration — All cosmetic manufacturing and processing facilities must register with the FDA. As of early 2025, there was already a 20-fold increase in mandatory filings compared to the old voluntary programs. If your facility produces both supplements and cosmetics, you need to ensure dual compliance.

Product Listing — Every cosmetic product marketed in the U.S. must be listed with the FDA, including ingredient lists and labeling details. This creates a transparent database that regulators can audit at any time.

Adverse Event Reporting — Companies must now notify the FDA of any serious health-related complaints within 15 business days. This requirement mirrors what supplement manufacturers are already accustomed to under 21 CFR Part 16, but it catches many cosmetics-only companies off guard.

Good Manufacturing Practices (GMP) — MoCRA mandates that cosmetics be manufactured in accordance with GMP standards. Supplement manufacturers who already follow 21 CFR Part 111 have a head start, but the specific cosmetic GMP requirements have their own nuances.

How FDA 21 CFR Part 11 Fits Into the Picture

While MoCRA sets the what of compliance, FDA 21 CFR Part 11 defines the how for digital record-keeping. Any electronic records or electronic signatures used to meet MoCRA or cGMP requirements must satisfy Part 11 standards.

The Three Non-Negotiables of Part 11

1. Immutable Audit Trails — Every change to a digital record must be captured in a tamper-evident audit trail that logs who made the change, when they made it, and why. You cannot simply overwrite a formulation record or delete a batch entry.

2. Electronic Signatures — When a quality manager signs off on a batch release or a formulation change, that electronic signature must be legally binding. It must be uniquely tied to one individual, verified at the time of signing, and permanently linked to the signed record.

3. System Validation — Your digital systems must be validated to ensure they perform as intended. This includes access controls, data integrity checks, and periodic system audits.

The Real Cost of Non-Compliance

The consequences of failing to meet these regulatory requirements are severe and escalating:

• Warning Letters — The FDA has significantly increased its issuance of warning letters related to record-keeping deficiencies. A single warning letter becomes public record and can damage supplier and retail relationships.
• Import Alerts — For companies sourcing internationally, non-compliant facilities can be placed on import alert, effectively blocking your raw materials at the border.
• Injunctions and Seizures — In serious cases, the FDA can seek court injunctions to halt manufacturing or seize non-compliant products.
• Financial Impact — Between legal fees, remediation costs, and lost revenue, a single FDA enforcement action can cost a small manufacturer $250,000 or more.

How Modern Platforms Solve the Compliance Problem

Manual paper records or unsecured PDFs are significant liabilities during an inspection. The era of filing cabinets and spreadsheet-based "audit trails" is over.

Modern manufacturing platforms now offer turnkey compliance that automates the most burdensome regulatory requirements:

• Automated Audit Trails — Every action is logged automatically with timestamps, user identification, and change descriptions. No manual documentation required.
• Built-In Electronic Signatures — E-signature workflows are embedded directly into batch release, formulation approval, and quality review processes.
• Validation-Ready Architecture — Systems designed from the ground up to meet Part 11 requirements eliminate the $100,000+ cost of custom software validation that legacy systems demand.
• Real-Time Adverse Event Tracking — Automated alerting systems help you meet the 15-day reporting window without relying on manual calendar reminders.

Your 2026 Compliance Action Plan

1. Audit your current record-keeping systems — Identify any gaps where electronic records don't meet Part 11 standards.
2. Register your facility — If you haven't already completed MoCRA facility registration, do so immediately.
3. Review your adverse event procedures — Ensure you have a documented process for reporting serious adverse events within 15 business days.
4. Evaluate your technology — Consider whether your current software provides the audit trails, e-signatures, and validation documentation that regulators expect.
5. Train your team — Compliance is only as strong as the people implementing it. Invest in training for every employee who touches regulated processes.

The regulatory environment is only going to get stricter. Manufacturers who invest in compliance infrastructure now will have a significant competitive advantage over those scrambling to catch up after an inspection finds deficiencies.